R&D Progress | SDTM001 Injection: Phase I Clinical Trial Advances Efficiently, Phase II Readiness Nears On May 13, Sedate Biological jointly held a strategic meeting with its partner CRO to discuss the Phase II clinical strategy for its core pipeline asset, SDTM001 Injection. Currently, the Phase I clinical trial is progressing steadily, with the Safety Review Committee (SRC) meetings for the low- and medium-dose groups completed and the high-dose administration phase underway. The program has preliminarily met the conditions to transition into Phase II, marking an acceleration of the development process. News 2026-05-13

Riding on the Wind and Riding a Horse Together on a New Journey The annual sequence changes, and the new chapter appears day by day. On January 22nd, the Cytocraft "Riding on the Wind, Embarking on a New Journey Together" themed annual meeting was grandly held at the Jinniu Hotel. All Cytocraft people gather together to welcome an annual grand ceremony that brings together cohesion, vision, and celebration. News 2026-01-23

Cytocraft has participated in two CAR-T cell therapy projects On November 25, 2025, the "Technical Specification for Clinical Application of CAR-T Cell Therapy" (standard number: T/ZGCIT 068-2025) and the "Quality Control and Release Inspection Specification for CAR-T Cell Products" (standard number: T/ZGCIT 067-2025) were officially released on the National Group Standard Information Platform and will be implemented from November 30, 2025. News 2026-01-14

Cell therapy incubation acceleration park laboratory sets sail On November 27th, the first phase of the Cell Therapy Incubation Acceleration Park Laboratory held a team entry ceremony. Representatives from Chengdu Development and Reform Commission, Jinniu District Government, financial institutions, and industry guests gathered together to witness the opening of this "glorious" moment. News 2025-11-27

Cytocraft Party Branch organizes all staff to watch the movie ‘731’ History is the best textbook and also the best sobering agent. In order to deeply remember the history of the Anti Japanese War, pay tribute to revolutionary martyrs, and further enhance the sense of national responsibility and historical mission of all employees, on the afternoon of September 19th, the Cytocraft Party branch organized all party members and employees to watch the historical themed film "731". News 2025-09-19

SDTM001 injection completed the first subject administration On September 8th, the Phase I clinical trial of Cytocraft's independently developed cell therapy new drug SDTM001 injection made critical progress - the first subject successfully completed drug administration at Yunnan Cancer Hospital. This marks the official launch of clinical research on this innovative therapy, bringing new hope for the treatment of non-small cell lung cancer (NSCLC) patients. News 2025-09-09

Consolidate patriotism and jointly build th September 3, 2025, is the 80th anniversary of the victory of the Chinese People's War of Resistance Against Japanese Aggression and the World Anti Fascist War. A grand military parade was held at Tiananmen Square in Beijing, demonstrating China's firm determination to maintain peace and its great power responsibility. News 2025-09-03

Phase I Multi-Center Clinical Study of Cytocraft sdtm001 Injection On May 20th, the SDTM001 injection independently developed by Cytocraft held the Phase I multicenter clinical kickoff meeting at its headquarters in Chengdu. This launch event is of great significance, not only marking Cytocraft's official entry into a crucial stage in the development of innovative drugs for non-small cell lung cancer (NSCLC), but also illuminating a new therapeutic dawn for many NSCLC patients. News 2025-05-21

Breaking the dilemma of liver cancer, opening a new chapter of life In the vast field of global pharmaceutical research and development, the emergence of innovative cell drugs is a key force in overcoming difficult diseases and improving human health. News 2025-05-12

Cytocraft core pipeline SDT-T001 approved for phase II clinical trials Recently, the SDT-T001 cell injection developed by the company has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration and entered Phase II clinical trials. This major milestone marks the company's crucial leap from research and development to the last mile of clinical trials! News 2025-04-24

Life Rhythm · Spring Start Jiuzhai | Cytocraft 2025 Theme Team Building Tour From April 18th to 20th, under the leadership of Chairman Wu Maoyou, the Cytocraft team embarked on a spring team building journey with the theme of "Life Rhythm · Spring Starts Jiuzhai". News 2025-04-21

Overseas layout has entered a substantive stage! Recently, Indra Widjaja, Chairman of Golden Light Financial Group, one of Indonesia's largest corporate groups, visited Cytocraft's Beijing R&D center and had in-depth exchanges with Cytocraft Chairman Wu Maoyou, CTO Dr. Gu Songhai, and senior executives in Beijing. News 2025-04-10